$77.09
1.17%
NYSE, Apr 21, 08:14 pm CET
ISIN
US58933Y1055
Symbol
MRK

Merck & Co. Stock price

$78.00
-16.79 17.71% 1M
-31.75 28.93% 6M
-21.48 21.59% YTD
-47.37 37.78% 1Y
-8.07 9.38% 3Y
-1.58 1.99% 5Y
+23.76 43.81% 10Y
NYSE, Closing price Thu, Apr 17 2025
+1.54 2.01%
ISIN
US58933Y1055
Symbol
MRK
Sector
Industry

Key metrics

Market capitalization $196.28b
Enterprise Value $220.84b
P/E (TTM) P/E ratio 11.58
EV/FCF (TTM) EV/FCF 12.20
EV/Sales (TTM) EV/Sales 3.45
P/S ratio (TTM) P/S ratio 3.07
P/B ratio (TTM) P/B ratio 4.26
Dividend yield 4.00%
Last dividend (FY24) $3.12
Revenue growth (TTM) Revenue growth 6.85%
Revenue (TTM) Revenue $63.97b
EBIT (operating result TTM) EBIT $21.35b
Free Cash Flow (TTM) Free Cash Flow $18.10b
Cash position $13.77b
EPS (TTM) EPS $6.73
P/E forward 9.18
P/S forward 3.02
EV/Sales forward 3.40
Short interest 1.50%
Show more

Create a Free Account to create an Merck & Co. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Merck & Co. forecast:

17x Buy
65%
9x Hold
35%

Analyst Opinions

26 Analysts have issued a Merck & Co. forecast:

Buy
65%
Hold
35%

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
63,973 63,973
7% 7%
100%
- Direct Costs 16,197 16,197
9% 9%
25%
47,776 47,776
13% 13%
75%
- Selling and Administrative Expenses 6,274 6,274
4% 4%
10%
- Research and Development Expense 15,726 15,726
45% 45%
25%
25,776 25,776
273% 273%
40%
- Depreciation and Amortization 4,431 4,431
14% 14%
7%
EBIT (Operating Income) EBIT 21,345 21,345
601% 601%
33%
Net Profit 17,117 17,117
4,590% 4,590%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Merck & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merck & Co. Stock News

Positive
Seeking Alpha
about 3 hours ago
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. New product launches like WINREVAIR are exceeding expectations and offsetting pipeline risk.
Positive
FXEmpire
about 6 hours ago
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Positive
24/7 Wall Street
3 days ago
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office United States
CEO Robert Davis
Employees 75,000
Founded 1891
Website www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today